{"name":"Hoffmann-La Roche","slug":"hoffmann-la-roche","ticker":"","exchange":"","domain":"","description":"F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. \nRoche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":700000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Alecensa","genericName":"alectinib","slug":"alectinib","revenue":700000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2015-01-01","label":"Alecensa first approved","drug":"Alecensa","drugSlug":"alectinib","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":700000000,"percentOfTotal":100,"drugCount":46,"colorKey":"oncology","drugs":[{"name":"Alecensa","genericName":"alectinib","slug":"alectinib","indication":"Anaplastic lymphoma kinase positive anaplastic large cell lymphoma","status":"marketed","revenue":700000000},{"name":"FEC Chemotherapy","genericName":"FEC Chemotherapy","slug":"fec-chemotherapy","indication":"Breast cancer (adjuvant and neoadjuvant treatment)","status":"phase_3"},{"name":"Ocrelizumab SC","genericName":"Ocrelizumab SC","slug":"ocrelizumab-sc","indication":"Relapsing forms of multiple sclerosis","status":"phase_3"},{"name":"5-Fluouracil","genericName":"5-Fluouracil","slug":"5-fluouracil","indication":"Colorectal cancer","status":"marketed"},{"name":"Ado-trastuzumab emtamsine","genericName":"Ado-trastuzumab emtamsine","slug":"ado-trastuzumab-emtamsine","indication":"Adjuvant treatment of HER2-positive breast cancer","status":"phase_2"},{"name":"Anti-EGFR-Containing Regimen","genericName":"Anti-EGFR-Containing Regimen","slug":"anti-egfr-containing-regimen","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"Anti-VEGF Therapy","genericName":"Anti-VEGF Therapy","slug":"anti-vegf-therapy","indication":"Metastatic colorectal cancer (in combination with chemotherapy)","status":"phase_3"},{"name":"Baseline Treatment","genericName":"Baseline Treatment","slug":"baseline-treatment","indication":"Metastatic non-small cell lung cancer","status":"phase_3"},{"name":"Bevacizumab-containing regimen","genericName":"Bevacizumab-containing regimen","slug":"bevacizumab-containing-regimen","indication":"Metastatic colorectal cancer","status":"phase_2"},{"name":"CDK4/6i","genericName":"CDK4/6i","slug":"cdk4-6i","indication":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (in combination with endocrine therapy)","status":"phase_3"},{"name":"Carboplatin-based chemotherapy","genericName":"Carboplatin-based chemotherapy","slug":"carboplatin-based-chemotherapy","indication":"Ovarian cancer","status":"phase_2"},{"name":"Epidoxorubicin","genericName":"Epidoxorubicin","slug":"epidoxorubicin","indication":"Carcinoma of breast","status":"phase_2"},{"name":"Erlotinib, standard dose","genericName":"Erlotinib, standard dose","slug":"erlotinib-standard-dose","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"FAP IL2V","genericName":"FAP IL2V","slug":"fap-il2v","indication":"Solid tumors (in clinical development)","status":"phase_3"},{"name":"FDC of Pertuzumab and Trastuzumab SC","genericName":"FDC of Pertuzumab and Trastuzumab SC","slug":"fdc-of-pertuzumab-and-trastuzumab-sc","indication":"HER2-positive metastatic breast cancer","status":"phase_3"},{"name":"FEC","genericName":"FEC","slug":"fec","indication":"Breast cancer (adjuvant and neoadjuvant treatment)","status":"marketed"},{"name":"FOLFOX induction regimen","genericName":"FOLFOX induction regimen","slug":"folfox-induction-regimen","indication":"Colorectal cancer","status":"phase_2"},{"name":"Fluoropyrimidine-based Chemotherapy","genericName":"Fluoropyrimidine-based Chemotherapy","slug":"fluoropyrimidine-based-chemotherapy","indication":"Colorectal cancer","status":"phase_3"},{"name":"Herceptin IV [trastuzumab]","genericName":"Herceptin IV [trastuzumab]","slug":"herceptin-iv-trastuzumab","indication":"HER2-positive metastatic breast cancer","status":"phase_3"},{"name":"Herceptin SC [trastuzumab]","genericName":"Herceptin SC [trastuzumab]","slug":"herceptin-sc-trastuzumab","indication":"HER2-positive metastatic breast cancer","status":"phase_3"},{"name":"Interferon alfa 2a [Roferon]","genericName":"Interferon alfa 2a [Roferon]","slug":"interferon-alfa-2a-roferon","indication":"Chronic myeloid leukemia (CML)","status":"phase_3"},{"name":"MabThera/Rituxan","genericName":"MabThera/Rituxan","slug":"mabthera-rituxan","indication":"Non-Hodgkin's lymphoma (B-cell)","status":"phase_3"},{"name":"Methotrexate (stable dose)","genericName":"Methotrexate (stable dose)","slug":"methotrexate-stable-dose","indication":"Acute lymphoblastic leukemia (ALL)","status":"marketed"},{"name":"Methotrexate (tapering dose)","genericName":"Methotrexate (tapering dose)","slug":"methotrexate-tapering-dose","indication":"Acute lymphoblastic leukemia (ALL)","status":"marketed"},{"name":"Other Combination Anti-Cancer Therapies","genericName":"Other Combination Anti-Cancer Therapies","slug":"other-combination-anti-cancer-therapies","indication":"Various solid tumors and hematologic malignancies (specific combinations vary by pipeline program)","status":"phase_3"},{"name":"Paclitaxel (Chemotherapy)","genericName":"Paclitaxel (Chemotherapy)","slug":"paclitaxel-chemotherapy","indication":"Metastatic carcinoma of the ovary","status":"phase_3"},{"name":"Pertuzumab IV","genericName":"Pertuzumab IV","slug":"pertuzumab-iv","indication":"HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy)","status":"phase_3"},{"name":"Pertuzumab and Trastuzumab FDC SC","genericName":"Pertuzumab and Trastuzumab FDC SC","slug":"pertuzumab-and-trastuzumab-fdc-sc","indication":"HER2-positive metastatic breast cancer","status":"phase_3"},{"name":"Physician's Choice of Endocrine Therapy","genericName":"Physician's Choice of Endocrine Therapy","slug":"physician-s-choice-of-endocrine-therapy","indication":"Treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer","status":"phase_3"},{"name":"Placebo for Atezolizumab","genericName":"Placebo for Atezolizumab","slug":"placebo-for-atezolizumab","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"Placebo to bevacizumab","genericName":"Placebo to bevacizumab","slug":"placebo-to-bevacizumab","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"Prednisone/Prednisolone/Methylprednisolone","genericName":"Prednisone/Prednisolone/Methylprednisolone","slug":"prednisone-prednisolone-methylprednisolone","indication":"Rheumatoid arthritis and other autoimmune inflammatory conditions","status":"marketed"},{"name":"RO0503821 (1x/2 Weeks)","genericName":"RO0503821 (1x/2 Weeks)","slug":"ro0503821-1x-2-weeks","indication":"Solid tumors or hematologic malignancies (specific indication not publicly disclosed)","status":"phase_3"},{"name":"RO4917838","genericName":"RO4917838","slug":"ro4917838","indication":"Metastatic non-small cell lung cancer","status":"phase_3"},{"name":"RO7234292","genericName":"RO7234292","slug":"ro7234292","indication":"Gastric cancer (gastric adenocarcinoma)","status":"phase_3"},{"name":"Rituximab IV","genericName":"Rituximab IV","slug":"rituximab-iv","indication":"Non-Hodgkin's lymphoma","status":"phase_3"},{"name":"Second-Line Chemotherapy","genericName":"Second-Line Chemotherapy","slug":"second-line-chemotherapy","indication":"Advanced or metastatic cancers after first-line chemotherapy failure or progression","status":"phase_3"},{"name":"Streptozotocin","genericName":"Streptozotocin","slug":"streptozotocin","indication":"Pancreatic Neuroendocrine Tumor","status":"phase_3"},{"name":"Topotecan (Chemotherapy)","genericName":"Topotecan (Chemotherapy)","slug":"topotecan-chemotherapy","indication":"Metastatic ovarian cancer","status":"phase_3"},{"name":"Trastuzumab IV","genericName":"Trastuzumab IV","slug":"trastuzumab-iv","indication":"Adjuvant treatment of HER2-positive breast cancer","status":"phase_3"},{"name":"XELODA [capecitabine]","genericName":"XELODA [capecitabine]","slug":"xeloda-capecitabine","indication":"Metastatic colorectal cancer","status":"marketed"},{"name":"Zelboraf","genericName":"Zelboraf","slug":"zelboraf","indication":"Erdheim-Chester Disease","status":"marketed"},{"name":"epoetin beta [NeoRecormon]","genericName":"epoetin beta [NeoRecormon]","slug":"epoetin-beta-neorecormon","indication":"Anemia associated with chronic kidney disease","status":"marketed"},{"name":"ibandronate [Bonviva/Boniva]","genericName":"ibandronate [Bonviva/Boniva]","slug":"ibandronate-bonviva-boniva","indication":"Osteoporosis in postmenopausal women","status":"marketed"},{"name":"interferon-a-2a","genericName":"interferon-a-2a","slug":"interferon-a-2a","indication":"Multiple myeloma","status":"phase_3"},{"name":"rituximab [MabThera/Rituxan]","genericName":"rituximab [MabThera/Rituxan]","slug":"rituximab-mabthera-rituxan","indication":"Non-Hodgkin's lymphoma (B-cell)","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":62,"colorKey":"infectious","drugs":[{"name":"PI","genericName":"PI","slug":"pi","indication":"Other","status":"marketed"},{"name":"RG6496","genericName":"RG6496","slug":"rg6496","indication":"Other","status":"phase_1"},{"name":"14C-Labeled Vemurafenib","genericName":"14C-Labeled Vemurafenib","slug":"14c-labeled-vemurafenib","indication":"Other","status":"phase_1"},{"name":"203Pb-DOTAM","genericName":"203Pb-DOTAM","slug":"203pb-dotam","indication":"Other","status":"phase_1"},{"name":"212Pb-DOTAM","genericName":"212Pb-DOTAM","slug":"212pb-dotam","indication":"Other","status":"phase_1"},{"name":"89Zr-Df-IAB22M2C","genericName":"89Zr-Df-IAB22M2C","slug":"89zr-df-iab22m2c","indication":"Other","status":"phase_1"},{"name":"ANA773","genericName":"ANA773","slug":"ana773","indication":"Other","status":"phase_1"},{"name":"Actos","genericName":"Actos","slug":"actos","indication":"Other","status":"marketed"},{"name":"Alectnib","genericName":"Alectnib","slug":"alectnib","indication":"Other","status":"phase_3"},{"name":"Alimta or Taxotere","genericName":"Alimta or Taxotere","slug":"alimta-or-taxotere","indication":"Other","status":"phase_3"},{"name":"Balovaptan therapeutic dose Treatment A","genericName":"Balovaptan therapeutic dose Treatment A","slug":"balovaptan-therapeutic-dose-treatment-a","indication":"Other","status":"phase_1"},{"name":"Becavizumab","genericName":"Becavizumab","slug":"becavizumab","indication":"Other","status":"phase_3"},{"name":"Cellmune","genericName":"Cellmune","slug":"cellmune","indication":"Other","status":"phase_1"},{"name":"Copegus","genericName":"Copegus","slug":"copegus","indication":"Other","status":"marketed"},{"name":"Corticosteroids, PO","genericName":"Corticosteroids, PO","slug":"corticosteroids-po","indication":"Other","status":"marketed"},{"name":"Desloratadine given orally","genericName":"Desloratadine given orally","slug":"desloratadine-given-orally","indication":"Allergic rhinitis (seasonal and perennial)","status":"phase_3"},{"name":"Diphenhydramine IV","genericName":"Diphenhydramine IV","slug":"diphenhydramine-iv","indication":"Acute allergic reactions","status":"phase_3"},{"name":"Doxycline","genericName":"Doxycline","slug":"doxycline","indication":"Other","status":"phase_2"},{"name":"Epirubicine","genericName":"Epirubicine","slug":"epirubicine","indication":"Other","status":"phase_3"},{"name":"Erlotinib [Tarceva]","genericName":"Erlotinib [Tarceva]","slug":"erlotinib-tarceva","indication":"Other","status":"marketed"},{"name":"Etrozulimab","genericName":"Etrozulimab","slug":"etrozulimab","indication":"Other","status":"phase_3"},{"name":"Evidence-based medical care for Acute Coronary Syndrome","genericName":"Evidence-based medical care for Acute Coronary Syndrome","slug":"evidence-based-medical-care-for-acute-coronary-syndrome","indication":"Other","status":"phase_3"},{"name":"Fisiogel","genericName":"Fisiogel","slug":"fisiogel","indication":"Other","status":"phase_3"},{"name":"Hormone Therapy","genericName":"Hormone Therapy","slug":"hormone-therapy","indication":"Menopausal hormone therapy","status":"phase_3"},{"name":"IV Balovaptan","genericName":"IV Balovaptan","slug":"iv-balovaptan","indication":"Other","status":"phase_1"},{"name":"IV Glofitamab","genericName":"IV Glofitamab","slug":"iv-glofitamab","indication":"Other","status":"phase_1"},{"name":"LTRA","genericName":"LTRA","slug":"ltra","indication":"Other","status":"marketed"},{"name":"Mycept","genericName":"Mycept","slug":"mycept","indication":"Other","status":"phase_1"},{"name":"Mycophenolate mofetil, adjusted dose","genericName":"Mycophenolate mofetil, adjusted dose","slug":"mycophenolate-mofetil-adjusted-dose","indication":"Other","status":"marketed"},{"name":"NSAIDs","genericName":"NSAIDs","slug":"nsaids","indication":"Other","status":"marketed"},{"name":"Other Biologics","genericName":"Other Biologics","slug":"other-biologics","indication":"Other","status":"phase_2"},{"name":"PEG-IFN alfa-2a","genericName":"PEG-IFN alfa-2a","slug":"peg-ifn-alfa-2a","indication":"Other","status":"marketed"},{"name":"Peg-Interferon Alpha-2A","genericName":"Peg-Interferon Alpha-2A","slug":"peg-interferon-alpha-2a","indication":"Other","status":"marketed"},{"name":"Phesgo","genericName":"Phesgo","slug":"phesgo","indication":"Other","status":"marketed"},{"name":"Placebo (matching sitagliptin)","genericName":"Placebo (matching sitagliptin)","slug":"placebo-matching-sitagliptin","indication":"Other","status":"phase_3"},{"name":"Placebo Matched to MTX","genericName":"Placebo Matched to MTX","slug":"placebo-matched-to-mtx","indication":"Matched to Methotrexate (MTX) in clinical trials","status":"phase_3"},{"name":"Placebo Matched to Tocilizumab","genericName":"Placebo Matched to Tocilizumab","slug":"placebo-matched-to-tocilizumab","indication":"Other","status":"phase_3"},{"name":"Placebo for Ipatasertib","genericName":"Placebo for Ipatasertib","slug":"placebo-for-ipatasertib","indication":"Control arm in ipatasertib clinical trials (specific indication depends on the trial protocol)","status":"phase_3"},{"name":"Placebo matched to ocrelizumab","genericName":"Placebo matched to ocrelizumab","slug":"placebo-matched-to-ocrelizumab","indication":"Other","status":"phase_3"},{"name":"Placebo matched to prednisone","genericName":"Placebo matched to prednisone","slug":"placebo-matched-to-prednisone","indication":"Clinical trial control comparator (not a therapeutic indication)","status":"marketed"},{"name":"RO5027838","genericName":"RO5027838","slug":"ro5027838","indication":"Other","status":"phase_2"},{"name":"RO7121932 SC","genericName":"RO7121932 SC","slug":"ro7121932-sc","indication":"Other","status":"phase_1"},{"name":"RO7234292 (RG6042)","genericName":"RO7234292 (RG6042)","slug":"ro7234292-rg6042","indication":"Spinal muscular atrophy","status":"phase_3"},{"name":"RO7623066","genericName":"RO7623066","slug":"ro7623066","indication":"Other","status":"phase_1"},{"name":"Renodapt","genericName":"Renodapt","slug":"renodapt","indication":"Other","status":"phase_1"},{"name":"Rituxumab","genericName":"Rituxumab","slug":"rituxumab","indication":"Other","status":"phase_3"},{"name":"Ro 205-2349","genericName":"Ro 205-2349","slug":"ro-205-2349","indication":"Other","status":"phase_2"},{"name":"Satralizumab 120 mg","genericName":"Satralizumab 120 mg","slug":"satralizumab-120-mg","indication":"Other","status":"marketed"},{"name":"Sham Procedure","genericName":"Sham Procedure","slug":"sham-procedure","indication":"Various conditions","status":"phase_3"},{"name":"Silrolimus","genericName":"Silrolimus","slug":"silrolimus","indication":"Other","status":"marketed"},{"name":"Supportive treatment","genericName":"Supportive treatment","slug":"supportive-treatment","indication":"Other","status":"marketed"},{"name":"TT Vaccine","genericName":"TT Vaccine","slug":"tt-vaccine","indication":"Prevention of diphtheria and tetanus","status":"phase_3"},{"name":"Tociliuzumab","genericName":"Tociliuzumab","slug":"tociliuzumab","indication":"Other","status":"phase_2"},{"name":"Vitamin D and calcium supplementation","genericName":"Vitamin D and calcium supplementation","slug":"vitamin-d-and-calcium-supplementation","indication":"Osteoporosis prevention and treatment","status":"marketed"},{"name":"[ 14C]-labeled RO7269162","genericName":"[ 14C]-labeled RO7269162","slug":"14c-labeled-ro7269162","indication":"Other","status":"phase_1"},{"name":"[12C] RO7049389","genericName":"[12C] RO7049389","slug":"12c-ro7049389","indication":"Other","status":"phase_1"},{"name":"anti-IL-2R","genericName":"anti-IL-2R","slug":"anti-il-2r","indication":"Prevention of organ rejection in kidney transplant recipients","status":"phase_3"},{"name":"antihistamine","genericName":"antihistamine","slug":"antihistamine","indication":"Other","status":"marketed"},{"name":"eloxatin","genericName":"eloxatin","slug":"eloxatin","indication":"Other","status":"phase_2"},{"name":"enfuvirtide [Fuzeon]","genericName":"enfuvirtide [Fuzeon]","slug":"enfuvirtide-fuzeon","indication":"Other","status":"marketed"},{"name":"pemetrexel","genericName":"pemetrexel","slug":"pemetrexel","indication":"Other","status":"discontinued"},{"name":"tacrolimus, standard dose","genericName":"tacrolimus, standard dose","slug":"tacrolimus-standard-dose","indication":"Other","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":25,"colorKey":"cardiovascular","drugs":[{"name":"Corticosteroids, IV","genericName":"Corticosteroids, IV","slug":"corticosteroids-iv","indication":"Acute inflammatory and autoimmune disorders","status":"marketed"},{"name":"DT","genericName":"DT","slug":"dt","indication":"Active immunization against diphtheria and tetanus in infants and children","status":"marketed"},{"name":"Biological DMARDs","genericName":"Biological DMARDs","slug":"biological-dmards","indication":"Rheumatoid arthritis","status":"phase_2"},{"name":"CNI (50%)","genericName":"CNI (50%)","slug":"cni-50","indication":"Organ transplant rejection prophylaxis","status":"marketed"},{"name":"CNI (≥75%)","genericName":"CNI (≥75%)","slug":"cni-75","indication":"Organ transplant rejection prophylaxis (renal, cardiac, hepatic)","status":"marketed"},{"name":"CSs","genericName":"CSs","slug":"css","indication":"Inflammatory and autoimmune disorders","status":"marketed"},{"name":"Corticosteroid or NSAID","genericName":"Corticosteroid or NSAID","slug":"corticosteroid-or-nsaid","indication":"Inflammatory and autoimmune disorders (corticosteroids)","status":"marketed"},{"name":"Dexamethasone given orally","genericName":"Dexamethasone given orally","slug":"dexamethasone-given-orally","indication":"Inflammatory and autoimmune disorders (rheumatoid arthritis, systemic lupus erythematosus, vasculitis)","status":"phase_3"},{"name":"Disease-modifying anti-rheumatic drugs","genericName":"Disease-modifying anti-rheumatic drugs","slug":"disease-modifying-anti-rheumatic-drugs","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Mycophenoate Mofetil","genericName":"Mycophenoate Mofetil","slug":"mycophenoate-mofetil","indication":"Prevention of organ transplant rejection (renal, cardiac, hepatic)","status":"phase_3"},{"name":"Mycophenolate mofetil, Standard dose","genericName":"Mycophenolate mofetil, Standard dose","slug":"mycophenolate-mofetil-standard-dose","indication":"Prevention of organ rejection in renal transplant recipients","status":"marketed"},{"name":"Non-Biologic DMARDs","genericName":"Non-Biologic DMARDs","slug":"non-biologic-dmards","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Permitted DMARDs","genericName":"Permitted DMARDs","slug":"permitted-dmards","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Placebo matched to fenebrutinib","genericName":"Placebo matched to fenebrutinib","slug":"placebo-matched-to-fenebrutinib","indication":"Control arm in phase 3 trials for fenebrutinib-targeted indications (likely autoimmune/inflammatory conditions)","status":"phase_3"},{"name":"Placebo to Mycophenolate mofetil","genericName":"Placebo to Mycophenolate mofetil","slug":"placebo-to-mycophenolate-mofetil","indication":"Prevention of organ rejection in renal, cardiac, and hepatic transplant recipients","status":"marketed"},{"name":"Placebo to adalimumab","genericName":"Placebo to adalimumab","slug":"placebo-to-adalimumab","indication":"Clinical trial control arm (comparator to adalimumab in various inflammatory and autoimmune conditions)","status":"marketed"},{"name":"Placebo to tocilizumab","genericName":"Placebo to tocilizumab","slug":"placebo-to-tocilizumab","indication":"Rheumatoid arthritis (moderate to severe)","status":"marketed"},{"name":"calcipotriol hydrate [Daivonex]","genericName":"calcipotriol hydrate [Daivonex]","slug":"calcipotriol-hydrate-daivonex","indication":"Plaque psoriasis","status":"marketed"},{"name":"fusidic acid [Verutex]","genericName":"fusidic acid [Verutex]","slug":"fusidic-acid-verutex","indication":"Bacterial infections, including osteomyelitis and septic arthritis","status":"phase_3"},{"name":"non-biological DMARDs","genericName":"non-biological DMARDs","slug":"non-biological-dmards","indication":"Rheumatoid arthritis","status":"marketed"},{"name":"placebo to tocilizumab IV","genericName":"placebo to tocilizumab IV","slug":"placebo-to-tocilizumab-iv","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"placebo to tocilizumab SC","genericName":"placebo to tocilizumab SC","slug":"placebo-to-tocilizumab-sc","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"tocilizumab SC","genericName":"tocilizumab SC","slug":"tocilizumab-sc","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"tocilizumab [RoActemra/Actemra]","genericName":"tocilizumab [RoActemra/Actemra]","slug":"tocilizumab-roactemra-actemra","indication":"Rheumatoid arthritis (moderate to severe)","status":"marketed"},{"name":"valganciclovir [Valcyte]","genericName":"valganciclovir [Valcyte]","slug":"valganciclovir-valcyte","indication":"Cytomegalovirus (CMV) retinitis in immunocompromised patients (including HIV/AIDS)","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"immunology","drugs":[{"name":"23-PPV","genericName":"23-PPV","slug":"23-ppv","indication":"Prevention of invasive pneumococcal disease in adults","status":"phase_3"},{"name":"Background ARVs","genericName":"Background ARVs","slug":"background-arvs","indication":"HIV-1 infection (treatment and suppression)","status":"marketed"},{"name":"ANA598","genericName":"ANA598","slug":"ana598","indication":"Chronic hepatitis C","status":"phase_2"},{"name":"Copegus (ribavirin)","genericName":"Copegus (ribavirin)","slug":"copegus-ribavirin","indication":"Chronic hepatitis C (in combination with interferon alfa or direct-acting antivirals)","status":"marketed"},{"name":"FUZEON [enfuvirtide]","genericName":"FUZEON [enfuvirtide]","slug":"fuzeon-enfuvirtide","indication":"HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy","status":"marketed"},{"name":"Lamivudine (LAM)","genericName":"Lamivudine (LAM)","slug":"lamivudine-lam","indication":"HIV-1 infection (in combination with other antiretroviral agents)","status":"marketed"},{"name":"Optimized background ARV","genericName":"Optimized background ARV","slug":"optimized-background-arv","indication":"HIV-1 infection in treatment-experienced patients with documented resistance","status":"marketed"},{"name":"Oseltamivir IV","genericName":"Oseltamivir IV","slug":"oseltamivir-iv","indication":"Treatment of acute influenza infection in hospitalized patients","status":"phase_3"},{"name":"dexpantenol [Bepantol]","genericName":"dexpantenol [Bepantol]","slug":"dexpantenol-bepantol","indication":"Treatment of herpes simplex virus infections","status":"phase_3"},{"name":"erythromycin [Eritex]","genericName":"erythromycin [Eritex]","slug":"erythromycin-eritex","indication":"Acute bacterial exacerbation of chronic bronchitis","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"respiratory","drugs":[{"name":"11C-L-deprenyl-D2","genericName":"11C-L-deprenyl-D2","slug":"11c-l-deprenyl-d2","indication":"Depression","status":"phase_1"},{"name":"Ocrelizumab IV","genericName":"Ocrelizumab IV","slug":"ocrelizumab-iv","indication":"Relapsing-remitting multiple sclerosis (RRMS)","status":"phase_3"},{"name":"RO0503821 (1x/4 Weeks)","genericName":"RO0503821 (1x/4 Weeks)","slug":"ro0503821-1x-4-weeks","indication":"Relapsing forms of multiple sclerosis","status":"phase_3"},{"name":"bitopertin [RO4917838]","genericName":"bitopertin [RO4917838]","slug":"bitopertin-ro4917838","indication":"Schizophrenia","status":"phase_3"},{"name":"bitopertin [RO4917838] level 1","genericName":"bitopertin [RO4917838] level 1","slug":"bitopertin-ro4917838-level-1","indication":"Schizophrenia (negative and cognitive symptoms, as adjunctive therapy)","status":"phase_3"},{"name":"bitopertin [RO4917838] level 2","genericName":"bitopertin [RO4917838] level 2","slug":"bitopertin-ro4917838-level-2","indication":"Schizophrenia","status":"phase_3"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"neuroscience","drugs":[{"name":"FVIII Replacement","genericName":"FVIII Replacement","slug":"fviii-replacement","indication":"Hemophilia A","status":"phase_2"},{"name":"Activated Prothrombin Complex Concentrate","genericName":"Activated Prothrombin Complex Concentrate","slug":"activated-prothrombin-complex-concentrate","indication":"Treatment of bleeding episodes in patients with hemophilia A or B","status":"phase_2"},{"name":"Bypassing Agents","genericName":"Bypassing Agents","slug":"bypassing-agents","indication":"Hemophilia A with factor VIII inhibitors","status":"phase_3"},{"name":"Factor VIII (FVIII)","genericName":"Factor VIII (FVIII)","slug":"factor-viii-fviii","indication":"Hemophilia A (congenital Factor VIII deficiency)","status":"phase_3"},{"name":"Recombinant Activated Factor VII","genericName":"Recombinant Activated Factor VII","slug":"recombinant-activated-factor-vii","indication":"Hemophilia A or B with inhibitors","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"metabolic","drugs":[{"name":"DPP-IV Inhibitor","genericName":"DPP-IV Inhibitor","slug":"dpp-iv-inhibitor","indication":"Type 2 diabetes","status":"phase_2"},{"name":"GC33","genericName":"GC33","slug":"gc33","indication":"Type 2 diabetes","status":"phase_2"},{"name":"Ranibizumab refill exchange","genericName":"Ranibizumab refill exchange","slug":"ranibizumab-refill-exchange","indication":"Neovascular (wet) age-related macular degeneration","status":"phase_3"},{"name":"aleglitazar+metformin","genericName":"aleglitazar+metformin","slug":"aleglitazar-metformin","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"ophthalmology","drugs":[{"name":"Dalcetrapib (RO4607381)","genericName":"Dalcetrapib (RO4607381)","slug":"dalcetrapib-ro4607381","indication":"Cardiovascular risk reduction in patients with coronary heart disease or high cardiovascular risk (Phase 3 development)","status":"phase_3"},{"name":"Sefaxersen (RO7434656)","genericName":"Sefaxersen (RO7434656)","slug":"sefaxersen-ro7434656","indication":"Treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE)","status":"phase_3"},{"name":"aPCC","genericName":"aPCC","slug":"apcc","indication":"Reversal of anticoagulation due to warfarin or other vitamin K antagonists in patients with acute major bleeding or at high risk of bleeding","status":"phase_3"},{"name":"tacrolimus, low dose","genericName":"tacrolimus, low dose","slug":"tacrolimus-low-dose","indication":"Organ transplant rejection prophylaxis (kidney, heart, liver)","status":"marketed"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"rare","drugs":[{"name":"C.E.R.A.","genericName":"C.E.R.A.","slug":"c-e-r-a","indication":"Anemia associated with chronic kidney disease","status":"phase_2"},{"name":"Folic acid or folate","genericName":"Folic acid or folate","slug":"folic-acid-or-folate","indication":"Folic acid deficiency anemia","status":"phase_3"},{"name":"epoetin alfa or beta","genericName":"epoetin alfa or beta","slug":"epoetin-alfa-or-beta","indication":"Anemia associated with chronic kidney disease","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"dermatology","drugs":[{"name":"Izervay™","genericName":"Izervay™","slug":"izervay","indication":"Geographic atrophy secondary to age-related macular degeneration","status":"marketed"},{"name":"Syfovre™","genericName":"Syfovre™","slug":"syfovre","indication":"Geographic atrophy secondary to age-related macular degeneration (AMD)","status":"marketed"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"pain","drugs":[{"name":"OCR","genericName":"OCR","slug":"ocr","indication":"Contraception","status":"marketed"}]}],"pipeline":[{"name":"Alecensa","genericName":"alectinib","slug":"alectinib","phase":"marketed","mechanism":"Alecensa blocks the activity of the ALK protein, which is involved in the growth and spread of cancer cells.","indications":["Anaplastic lymphoma kinase positive anaplastic large cell lymphoma","Non-small cell lung cancer"],"catalyst":""},{"name":"23-PPV","genericName":"23-PPV","slug":"23-ppv","phase":"phase_3","mechanism":"23-PPV is a pneumococcal polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae.","indications":["Prevention of invasive pneumococcal disease in adults","Prevention of pneumococcal pneumonia and related infections"],"catalyst":""},{"name":"Background ARVs","genericName":"Background ARVs","slug":"background-arvs","phase":"marketed","mechanism":"Background ARVs are antiretroviral drugs that suppress HIV replication through various mechanisms including reverse transcriptase inhibition, protease inhibition, and integrase inhibition.","indications":["HIV-1 infection (treatment and suppression)"],"catalyst":""},{"name":"Corticosteroids, IV","genericName":"Corticosteroids, IV","slug":"corticosteroids-iv","phase":"marketed","mechanism":"Corticosteroids suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","indications":["Acute inflammatory and autoimmune disorders","Severe allergic reactions","Cerebral edema","Acute exacerbations of chronic inflammatory conditions","Immunosuppression in transplantation"],"catalyst":""},{"name":"DT","genericName":"DT","slug":"dt","phase":"marketed","mechanism":"DT is a diphtheria and tetanus toxoid vaccine that stimulates the immune system to produce antibodies against diphtheria and tetanus toxins.","indications":["Active immunization against diphtheria and tetanus in infants and children"],"catalyst":""},{"name":"FEC Chemotherapy","genericName":"FEC Chemotherapy","slug":"fec-chemotherapy","phase":"phase_3","mechanism":"FEC is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division.","indications":["Breast cancer (adjuvant and neoadjuvant treatment)","Early-stage and locally advanced breast cancer"],"catalyst":""},{"name":"FVIII Replacement","genericName":"FVIII Replacement","slug":"fviii-replacement","phase":"phase_2","mechanism":"Recombinant FVIII replacement to correct FVIII deficiency","indications":["Hemophilia A"],"catalyst":""},{"name":"Ocrelizumab SC","genericName":"Ocrelizumab SC","slug":"ocrelizumab-sc","phase":"phase_3","mechanism":"Ocrelizumab SC is a monoclonal antibody that targets CD20 on B cells.","indications":["Relapsing forms of multiple sclerosis","Primary progressive multiple sclerosis","Non-Hodgkin's lymphoma"],"catalyst":""},{"name":"PI","genericName":"PI","slug":"pi","phase":"marketed","mechanism":"PI is a protease inhibitor that blocks viral protease activity, preventing the maturation and replication of viruses.","indications":[],"catalyst":""},{"name":"RG6496","genericName":"RG6496","slug":"rg6496","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"11C-L-deprenyl-D2","genericName":"11C-L-deprenyl-D2","slug":"11c-l-deprenyl-d2","phase":"phase_1","mechanism":"Selective norepinephrine reuptake inhibitor","indications":["Depression"],"catalyst":""},{"name":"14C-Labeled Vemurafenib","genericName":"14C-Labeled Vemurafenib","slug":"14c-labeled-vemurafenib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"203Pb-DOTAM","genericName":"203Pb-DOTAM","slug":"203pb-dotam","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"212Pb-DOTAM","genericName":"212Pb-DOTAM","slug":"212pb-dotam","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"5-Fluouracil","genericName":"5-Fluouracil","slug":"5-fluouracil","phase":"marketed","mechanism":"5-Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into RNA and DNA, disrupting nucleotide synthesis and causing cancer cell death.","indications":["Colorectal cancer","Breast cancer","Gastric cancer","Pancreatic cancer","Head and neck cancer"],"catalyst":""},{"name":"89Zr-Df-IAB22M2C","genericName":"89Zr-Df-IAB22M2C","slug":"89zr-df-iab22m2c","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ANA598","genericName":"ANA598","slug":"ana598","phase":"phase_2","mechanism":"ANA598 is a non-nucleoside inhibitor of the NS5B polymerase of the hepatitis C virus.","indications":["Chronic hepatitis C"],"catalyst":""},{"name":"ANA773","genericName":"ANA773","slug":"ana773","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Activated Prothrombin Complex Concentrate","genericName":"Activated Prothrombin Complex Concentrate","slug":"activated-prothrombin-complex-concentrate","phase":"phase_2","mechanism":"Activated Prothrombin Complex Concentrate works by replacing clotting factors to help the blood to clot.","indications":["Treatment of bleeding episodes in patients with hemophilia A or B","Treatment of bleeding in patients with acquired hemophilia A"],"catalyst":""},{"name":"Actos","genericName":"Actos","slug":"actos","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ado-trastuzumab emtamsine","genericName":"Ado-trastuzumab emtamsine","slug":"ado-trastuzumab-emtamsine","phase":"phase_2","mechanism":"Ado-trastuzumab emtansine is a HER2-targeting antibody-drug conjugate that delivers a cytotoxic agent to HER2-positive cancer cells.","indications":["Adjuvant treatment of HER2-positive breast cancer"],"catalyst":""},{"name":"Alectnib","genericName":"Alectnib","slug":"alectnib","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Alimta or Taxotere","genericName":"Alimta or Taxotere","slug":"alimta-or-taxotere","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Anti-EGFR-Containing Regimen","genericName":"Anti-EGFR-Containing Regimen","slug":"anti-egfr-containing-regimen","phase":"phase_2","mechanism":"Inhibits the epidermal growth factor receptor (EGFR)","indications":["Non-small cell lung cancer"],"catalyst":""},{"name":"Anti-VEGF Therapy","genericName":"Anti-VEGF Therapy","slug":"anti-vegf-therapy","phase":"phase_3","mechanism":"Anti-VEGF therapy blocks vascular endothelial growth factor (VEGF), a key signaling protein that promotes abnormal blood vessel formation in tumors and certain eye diseases.","indications":["Metastatic colorectal cancer (in combination with chemotherapy)","Non-small cell lung cancer","Metastatic renal cell carcinoma","Glioblastoma","Wet age-related macular degeneration"],"catalyst":""},{"name":"Balovaptan therapeutic dose Treatment A","genericName":"Balovaptan therapeutic dose Treatment A","slug":"balovaptan-therapeutic-dose-treatment-a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Baseline Treatment","genericName":"Baseline Treatment","slug":"baseline-treatment","phase":"phase_3","mechanism":"Baseline treatment is a type of therapy that aims to establish a standard level of treatment for a particular disease or condition.","indications":["Metastatic non-small cell lung cancer"],"catalyst":""},{"name":"Becavizumab","genericName":"Becavizumab","slug":"becavizumab","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Bevacizumab-containing regimen","genericName":"Bevacizumab-containing regimen","slug":"bevacizumab-containing-regimen","phase":"phase_2","mechanism":"Bevacizumab-containing regimens work by inhibiting angiogenesis through the blockade of vascular endothelial growth factor A (VEGF-A).","indications":["Metastatic colorectal cancer","Non-small cell lung cancer","Breast cancer","Glioblastoma","Renal cell carcinoma"],"catalyst":""},{"name":"Biological DMARDs","genericName":"Biological DMARDs","slug":"biological-dmards","phase":"phase_2","mechanism":"Biological DMARDs work by targeting specific proteins involved in the immune response to reduce inflammation and slow disease progression.","indications":["Rheumatoid arthritis","Psoriatic arthritis","Juvenile idiopathic arthritis"],"catalyst":""},{"name":"Bypassing Agents","genericName":"Bypassing Agents","slug":"bypassing-agents","phase":"phase_3","mechanism":"Bypassing agents are coagulation factors that activate the coagulation cascade downstream of factors VIII and IX to restore thrombin generation in patients with inhibitors to these factors.","indications":["Hemophilia A with factor VIII inhibitors","Hemophilia B with factor IX inhibitors","Bleeding episodes in inhibitor patients"],"catalyst":""},{"name":"C.E.R.A.","genericName":"C.E.R.A.","slug":"c-e-r-a","phase":"phase_2","mechanism":"C.E.R.A. is a continuous erythropoietin receptor activator.","indications":["Anemia associated with chronic kidney disease"],"catalyst":""},{"name":"CDK4/6i","genericName":"CDK4/6i","slug":"cdk4-6i","phase":"phase_3","mechanism":"CDK4/6 inhibitors block cyclin-dependent kinases 4 and 6, which prevents phosphorylation of the retinoblastoma protein and halts cell cycle progression in G1 phase.","indications":["Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (in combination with endocrine therapy)","Other CDK4/6-dependent malignancies in clinical development"],"catalyst":""},{"name":"CNI (50%)","genericName":"CNI (50%)","slug":"cni-50","phase":"marketed","mechanism":"CNI (calcineurin inhibitor) suppresses T-cell activation by inhibiting calcineurin phosphatase, thereby reducing production of pro-inflammatory cytokines.","indications":["Organ transplant rejection prophylaxis","Autoimmune and inflammatory conditions (e.g., atopic dermatitis, psoriasis)"],"catalyst":""},{"name":"CNI (≥75%)","genericName":"CNI (≥75%)","slug":"cni-75","phase":"marketed","mechanism":"CNI (calcineurin inhibitor) suppresses T-cell activation by inhibiting calcineurin phosphatase, thereby blocking IL-2 production and T-cell proliferation.","indications":["Organ transplant rejection prophylaxis (renal, cardiac, hepatic)","Autoimmune diseases (atopic dermatitis, psoriasis, rheumatoid arthritis)"],"catalyst":""},{"name":"CSs","genericName":"CSs","slug":"css","phase":"marketed","mechanism":"CSs likely refers to corticosteroids, which suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","indications":["Inflammatory and autoimmune disorders","Allergic reactions","Respiratory conditions (asthma, COPD)","Rheumatologic diseases"],"catalyst":""},{"name":"Carboplatin-based chemotherapy","genericName":"Carboplatin-based chemotherapy","slug":"carboplatin-based-chemotherapy","phase":"phase_2","mechanism":"Platinum-based DNA alkylating agent","indications":["Ovarian cancer","Breast cancer","Lung cancer"],"catalyst":""},{"name":"Cellmune","genericName":"Cellmune","slug":"cellmune","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Copegus","genericName":"Copegus","slug":"copegus","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Copegus (ribavirin)","genericName":"Copegus (ribavirin)","slug":"copegus-ribavirin","phase":"marketed","mechanism":"Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with the viral polymerase and depleting guanosine nucleotide pools.","indications":["Chronic hepatitis C (in combination with interferon alfa or direct-acting antivirals)","Severe respiratory syncytial virus (RSV) infection in hospitalized patients"],"catalyst":""},{"name":"Corticosteroid or NSAID","genericName":"Corticosteroid or NSAID","slug":"corticosteroid-or-nsaid","phase":"marketed","mechanism":"Corticosteroids suppress immune and inflammatory responses by binding glucocorticoid receptors, while NSAIDs inhibit cyclooxygenase enzymes to reduce prostaglandin production and inflammation.","indications":["Inflammatory and autoimmune disorders (corticosteroids)","Pain and inflammation management (NSAIDs)"],"catalyst":""},{"name":"Corticosteroids, PO","genericName":"Corticosteroids, PO","slug":"corticosteroids-po","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DPP-IV Inhibitor","genericName":"DPP-IV Inhibitor","slug":"dpp-iv-inhibitor","phase":"phase_2","mechanism":"DPP-IV inhibitors block the action of dipeptidyl peptidase-4, an enzyme that breaks down incretin hormones, thereby increasing incretin levels and enhancing glucose-dependent insulin secretion.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Dalcetrapib (RO4607381)","genericName":"Dalcetrapib (RO4607381)","slug":"dalcetrapib-ro4607381","phase":"phase_3","mechanism":"Dalcetrapib inhibits cholesteryl ester transfer protein (CETP) to increase HDL cholesterol and reduce LDL cholesterol levels.","indications":["Cardiovascular risk reduction in patients with coronary heart disease or high cardiovascular risk (Phase 3 development)"],"catalyst":""},{"name":"Desloratadine given orally","genericName":"Desloratadine given orally","slug":"desloratadine-given-orally","phase":"phase_3","mechanism":"Desloratadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses without significant central nervous system penetration.","indications":["Allergic rhinitis (seasonal and perennial)","Chronic idiopathic urticaria"],"catalyst":""},{"name":"Dexamethasone given orally","genericName":"Dexamethasone given orally","slug":"dexamethasone-given-orally","phase":"phase_3","mechanism":"Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm.","indications":["Inflammatory and autoimmune disorders (rheumatoid arthritis, systemic lupus erythematosus, vasculitis)","Cerebral edema and increased intracranial pressure","Adrenocortical insufficiency","Severe allergic reactions","Certain hematologic malignancies (as adjunctive therapy)"],"catalyst":""},{"name":"Diphenhydramine IV","genericName":"Diphenhydramine IV","slug":"diphenhydramine-iv","phase":"phase_3","mechanism":"Diphenhydramine is a first-generation antihistamine that blocks H1 histamine receptors to reduce allergic and inflammatory responses.","indications":["Acute allergic reactions","Anaphylaxis (adjunctive therapy)","Urticaria and pruritus","Allergic rhinitis"],"catalyst":""},{"name":"Disease-modifying anti-rheumatic drugs","genericName":"Disease-modifying anti-rheumatic drugs","slug":"disease-modifying-anti-rheumatic-drugs","phase":"phase_3","mechanism":"Disease-modifying anti-rheumatic drugs (DMARDs) suppress the underlying immune-mediated inflammatory processes that drive rheumatoid arthritis and other autoimmune conditions.","indications":["Rheumatoid arthritis","Other autoimmune inflammatory conditions (varies by specific DMARD)"],"catalyst":""},{"name":"Doxycline","genericName":"Doxycline","slug":"doxycline","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Epidoxorubicin","genericName":"Epidoxorubicin","slug":"epidoxorubicin","phase":"phase_2","mechanism":"Tyrosine-protein kinase Fyn, 5-hydroxytryptamine receptor 4, Genome polyprotein","indications":["Carcinoma of breast"],"catalyst":""},{"name":"Epirubicine","genericName":"Epirubicine","slug":"epirubicine","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Erlotinib [Tarceva]","genericName":"Erlotinib [Tarceva]","slug":"erlotinib-tarceva","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Erlotinib, standard dose","genericName":"Erlotinib, standard dose","slug":"erlotinib-standard-dose","phase":"phase_2","mechanism":"Erlotinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR) tyrosine kinase.","indications":["Non-small cell lung cancer","Pancreatic cancer"],"catalyst":""},{"name":"Etrozulimab","genericName":"Etrozulimab","slug":"etrozulimab","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Evidence-based medical care for Acute Coronary Syndrome","genericName":"Evidence-based medical care for Acute Coronary Syndrome","slug":"evidence-based-medical-care-for-acute-coronary-syndrome","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"FAP IL2V","genericName":"FAP IL2V","slug":"fap-il2v","phase":"phase_3","mechanism":"FAP IL2V is a bispecific immunotherapy that targets fibroblast activation protein (FAP) on cancer-associated fibroblasts while delivering interleukin-2 (IL-2) to activate anti-tumor immune responses.","indications":["Solid tumors (in clinical development)","Cancer-associated fibroblast-rich tumors"],"catalyst":""},{"name":"FDC of Pertuzumab and Trastuzumab SC","genericName":"FDC of Pertuzumab and Trastuzumab SC","slug":"fdc-of-pertuzumab-and-trastuzumab-sc","phase":"phase_3","mechanism":"This fixed-dose combination of two monoclonal antibodies blocks HER2 signaling by targeting the HER2 receptor from different epitopes, preventing tumor cell growth and survival.","indications":["HER2-positive metastatic breast cancer","HER2-positive early breast cancer (neoadjuvant and adjuvant settings)"],"catalyst":""},{"name":"FEC","genericName":"FEC","slug":"fec","phase":"marketed","mechanism":"FEC is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division.","indications":["Breast cancer (adjuvant and neoadjuvant treatment)","Metastatic breast cancer"],"catalyst":""},{"name":"FOLFOX induction regimen","genericName":"FOLFOX induction regimen","slug":"folfox-induction-regimen","phase":"phase_2","mechanism":"Oxaliplatin inhibits DNA replication by binding to DNA and inducing DNA damage.","indications":["Colorectal cancer"],"catalyst":""},{"name":"FUZEON [enfuvirtide]","genericName":"FUZEON [enfuvirtide]","slug":"fuzeon-enfuvirtide","phase":"marketed","mechanism":"Enfuvirtide blocks HIV from entering CD4+ T cells by binding to the gp41 fusion protein on the viral envelope and preventing membrane fusion.","indications":["HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy"],"catalyst":""},{"name":"Factor VIII (FVIII)","genericName":"Factor VIII (FVIII)","slug":"factor-viii-fviii","phase":"phase_3","mechanism":"Factor VIII is a clotting factor that replaces deficient or dysfunctional coagulation factor VIII to restore blood clotting ability in hemophilia A patients.","indications":["Hemophilia A (congenital Factor VIII deficiency)","Acquired hemophilia A"],"catalyst":""},{"name":"Fisiogel","genericName":"Fisiogel","slug":"fisiogel","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fluoropyrimidine-based Chemotherapy","genericName":"Fluoropyrimidine-based Chemotherapy","slug":"fluoropyrimidine-based-chemotherapy","phase":"phase_3","mechanism":"Fluoropyrimidine-based chemotherapy inhibits thymidylate synthase and incorporates into DNA/RNA to disrupt cancer cell replication and survival.","indications":["Colorectal cancer","Gastric cancer","Breast cancer","Pancreatic cancer","Head and neck cancer"],"catalyst":""},{"name":"Folic acid or folate","genericName":"Folic acid or folate","slug":"folic-acid-or-folate","phase":"phase_3","mechanism":"Folic acid acts as a coenzyme in one-carbon transfer reactions essential for DNA synthesis and cell division.","indications":["Folic acid deficiency anemia","Neural tube defect prevention in pregnancy","Megaloblastic anemia","Nutritional supplementation in various disease states"],"catalyst":""},{"name":"GC33","genericName":"GC33","slug":"gc33","phase":"phase_2","mechanism":"GC33 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Herceptin IV [trastuzumab]","genericName":"Herceptin IV [trastuzumab]","slug":"herceptin-iv-trastuzumab","phase":"phase_3","mechanism":"Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death.","indications":["HER2-positive metastatic breast cancer","HER2-positive early-stage breast cancer (adjuvant and neoadjuvant settings)","HER2-positive metastatic gastric cancer"],"catalyst":""},{"name":"Herceptin SC [trastuzumab]","genericName":"Herceptin SC [trastuzumab]","slug":"herceptin-sc-trastuzumab","phase":"phase_3","mechanism":"Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death.","indications":["HER2-positive metastatic breast cancer","HER2-positive early-stage breast cancer (adjuvant and neoadjuvant settings)","HER2-positive metastatic gastric cancer"],"catalyst":""},{"name":"Hormone Therapy","genericName":"Hormone Therapy","slug":"hormone-therapy","phase":"phase_3","mechanism":"Hormone therapy replaces or modulates endogenous hormones to treat deficiency states or hormone-sensitive conditions.","indications":["Menopausal hormone therapy","Hormone replacement in hypogonadism","Thyroid hormone replacement","Adrenal insufficiency"],"catalyst":""},{"name":"IV Balovaptan","genericName":"IV Balovaptan","slug":"iv-balovaptan","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IV Glofitamab","genericName":"IV Glofitamab","slug":"iv-glofitamab","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Interferon alfa 2a [Roferon]","genericName":"Interferon alfa 2a [Roferon]","slug":"interferon-alfa-2a-roferon","phase":"phase_3","mechanism":"Interferon alfa-2a activates the immune system by binding to interferon-alpha receptors on cell surfaces, enhancing natural killer cell and macrophage activity to fight viral infections and cancer cells.","indications":["Chronic myeloid leukemia (CML)","Hairy cell leukemia","Chronic hepatitis B","Chronic hepatitis C","Melanoma (adjuvant therapy)"],"catalyst":""},{"name":"Izervay™","genericName":"Izervay™","slug":"izervay","phase":"marketed","mechanism":"Izervay is a complement C3 inhibitor that blocks the central complement pathway to reduce inflammation and tissue damage in retinal diseases.","indications":["Geographic atrophy secondary to age-related macular degeneration"],"catalyst":""},{"name":"LTRA","genericName":"LTRA","slug":"ltra","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lamivudine (LAM)","genericName":"Lamivudine (LAM)","slug":"lamivudine-lam","phase":"marketed","mechanism":"Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV and hepatitis B virus replication by inhibiting the reverse transcriptase enzyme.","indications":["HIV-1 infection (in combination with other antiretroviral agents)","Chronic hepatitis B infection"],"catalyst":""},{"name":"MabThera/Rituxan","genericName":"MabThera/Rituxan","slug":"mabthera-rituxan","phase":"phase_3","mechanism":"Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system.","indications":["Non-Hodgkin's lymphoma (B-cell)","Chronic lymphocytic leukemia (CLL)","Rheumatoid arthritis","Granulomatosis with polyangiitis (GPA)","Microscopic polyangiitis (MPA)"],"catalyst":""},{"name":"Methotrexate (stable dose)","genericName":"Methotrexate (stable dose)","slug":"methotrexate-stable-dose","phase":"marketed","mechanism":"Methotrexate inhibits dihydrofolate reductase, blocking the synthesis of purines and pyrimidines required for DNA replication and cell division.","indications":["Acute lymphoblastic leukemia (ALL)","Osteosarcoma","Breast cancer","Lung cancer","Rheumatoid arthritis"],"catalyst":""},{"name":"Methotrexate (tapering dose)","genericName":"Methotrexate (tapering dose)","slug":"methotrexate-tapering-dose","phase":"marketed","mechanism":"Methotrexate inhibits dihydrofolate reductase, blocking the synthesis of purines and pyrimidines required for DNA replication and cell division.","indications":["Acute lymphoblastic leukemia (ALL)","Osteosarcoma","Breast cancer","Lung cancer","Rheumatoid arthritis"],"catalyst":""},{"name":"Mycept","genericName":"Mycept","slug":"mycept","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Mycophenoate Mofetil","genericName":"Mycophenoate Mofetil","slug":"mycophenoate-mofetil","phase":"phase_3","mechanism":"Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent immune rejection.","indications":["Prevention of organ transplant rejection (renal, cardiac, hepatic)","Active lupus nephritis","Autoimmune conditions requiring immunosuppression"],"catalyst":""},{"name":"Mycophenolate mofetil, Standard dose","genericName":"Mycophenolate mofetil, Standard dose","slug":"mycophenolate-mofetil-standard-dose","phase":"marketed","mechanism":"Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent organ rejection and autoimmune responses.","indications":["Prevention of organ rejection in renal transplant recipients","Prevention of organ rejection in cardiac transplant recipients","Prevention of organ rejection in hepatic transplant recipients","Active lupus nephritis (in combination with corticosteroids)"],"catalyst":""},{"name":"Mycophenolate mofetil, adjusted dose","genericName":"Mycophenolate mofetil, adjusted dose","slug":"mycophenolate-mofetil-adjusted-dose","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"NSAIDs","genericName":"NSAIDs","slug":"nsaids","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Non-Biologic DMARDs","genericName":"Non-Biologic DMARDs","slug":"non-biologic-dmards","phase":"phase_3","mechanism":"Non-biologic DMARDs are small-molecule drugs that suppress the immune system to reduce inflammation and slow disease progression in rheumatoid arthritis and other autoimmune conditions.","indications":["Rheumatoid arthritis","Other autoimmune inflammatory conditions"],"catalyst":""},{"name":"OCR","genericName":"OCR","slug":"ocr","phase":"marketed","mechanism":"OCR is an oral contraceptive containing ethinylestradiol and norgestimate that prevents pregnancy by suppressing ovulation and altering cervical mucus.","indications":["Contraception","Acne vulgaris (moderate)","Menorrhagia / heavy menstrual bleeding"],"catalyst":""},{"name":"Ocrelizumab IV","genericName":"Ocrelizumab IV","slug":"ocrelizumab-iv","phase":"phase_3","mechanism":"Ocrelizumab is a monoclonal antibody that depletes B cells by binding to CD20, reducing autoimmune-mediated inflammation.","indications":["Relapsing-remitting multiple sclerosis (RRMS)","Primary progressive multiple sclerosis (PPMS)"],"catalyst":""},{"name":"Optimized background ARV","genericName":"Optimized background ARV","slug":"optimized-background-arv","phase":"marketed","mechanism":"Optimized background ARV refers to a tailored combination of antiretroviral drugs selected based on individual patient resistance testing and treatment history to maximize viral suppression in HIV infection.","indications":["HIV-1 infection in treatment-experienced patients with documented resistance"],"catalyst":""},{"name":"Oseltamivir IV","genericName":"Oseltamivir IV","slug":"oseltamivir-iv","phase":"phase_3","mechanism":"Oseltamivir is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells, reducing viral spread.","indications":["Treatment of acute influenza infection in hospitalized patients","Prophylaxis of influenza in high-risk patients"],"catalyst":""},{"name":"Other Biologics","genericName":"Other Biologics","slug":"other-biologics","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Other Combination Anti-Cancer Therapies","genericName":"Other Combination Anti-Cancer Therapies","slug":"other-combination-anti-cancer-therapies","phase":"phase_3","mechanism":"This is a category descriptor for multiple combination anti-cancer therapies rather than a single drug, typically involving synergistic use of two or more oncologic agents.","indications":["Various solid tumors and hematologic malignancies (specific combinations vary by pipeline program)"],"catalyst":""},{"name":"PEG-IFN alfa-2a","genericName":"PEG-IFN alfa-2a","slug":"peg-ifn-alfa-2a","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Paclitaxel (Chemotherapy)","genericName":"Paclitaxel (Chemotherapy)","slug":"paclitaxel-chemotherapy","phase":"phase_3","mechanism":"Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.","indications":["Metastatic carcinoma of the ovary","Breast cancer (metastatic and adjuvant)","Non-small cell lung cancer","Kaposi sarcoma","Gastric adenocarcinoma"],"catalyst":""},{"name":"Peg-Interferon Alpha-2A","genericName":"Peg-Interferon Alpha-2A","slug":"peg-interferon-alpha-2a","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Permitted DMARDs","genericName":"Permitted DMARDs","slug":"permitted-dmards","phase":"phase_3","mechanism":"DMARDs (Disease-Modifying Antirheumatic Drugs) suppress immune system activity to reduce inflammation and slow progression of autoimmune diseases.","indications":["Rheumatoid arthritis","Other autoimmune inflammatory conditions"],"catalyst":""},{"name":"Pertuzumab IV","genericName":"Pertuzumab IV","slug":"pertuzumab-iv","phase":"phase_3","mechanism":"Pertuzumab is a monoclonal antibody that blocks HER2 dimerization, preventing HER2 from pairing with other HER receptors and inhibiting tumor cell growth signaling.","indications":["HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy)","HER2-positive early-stage breast cancer (adjuvant and neoadjuvant settings)","HER2-positive gastric cancer"],"catalyst":""},{"name":"Pertuzumab and Trastuzumab FDC SC","genericName":"Pertuzumab and Trastuzumab FDC SC","slug":"pertuzumab-and-trastuzumab-fdc-sc","phase":"phase_3","mechanism":"This fixed-dose combination of two monoclonal antibodies blocks HER2 signaling by targeting different epitopes on the HER2 receptor, preventing tumor cell growth and survival.","indications":["HER2-positive metastatic breast cancer","HER2-positive early breast cancer (neoadjuvant and adjuvant settings)"],"catalyst":""},{"name":"Phesgo","genericName":"Phesgo","slug":"phesgo","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Physician's Choice of Endocrine Therapy","genericName":"Physician's Choice of Endocrine Therapy","slug":"physician-s-choice-of-endocrine-therapy","phase":"phase_3","mechanism":"Physician's Choice of Endocrine Therapy is a treatment that targets hormone receptors to prevent or slow the growth of cancer cells.","indications":["Treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer"],"catalyst":""},{"name":"Placebo (matching sitagliptin)","genericName":"Placebo (matching sitagliptin)","slug":"placebo-matching-sitagliptin","phase":"phase_3","mechanism":"This drug has no known mechanism of action.","indications":[],"catalyst":""},{"name":"Placebo Matched to MTX","genericName":"Placebo Matched to MTX","slug":"placebo-matched-to-mtx","phase":"phase_3","mechanism":"This drug is a placebo, meaning it has no active therapeutic effect.","indications":["Matched to Methotrexate (MTX) in clinical trials"],"catalyst":""},{"name":"Placebo Matched to Tocilizumab","genericName":"Placebo Matched to Tocilizumab","slug":"placebo-matched-to-tocilizumab","phase":"phase_3","mechanism":"This is a placebo control arm matched to tocilizumab, an IL-6 receptor antagonist, and contains no active pharmaceutical ingredient.","indications":[],"catalyst":""},{"name":"Placebo for Atezolizumab","genericName":"Placebo for Atezolizumab","slug":"placebo-for-atezolizumab","phase":"phase_3","mechanism":"This is a placebo, meaning it has no active therapeutic effect.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"Placebo for Ipatasertib","genericName":"Placebo for Ipatasertib","slug":"placebo-for-ipatasertib","phase":"phase_3","mechanism":"This is a placebo control and has no active pharmacological mechanism.","indications":["Control arm in ipatasertib clinical trials (specific indication depends on the trial protocol)"],"catalyst":""},{"name":"Placebo matched to fenebrutinib","genericName":"Placebo matched to fenebrutinib","slug":"placebo-matched-to-fenebrutinib","phase":"phase_3","mechanism":"This is a placebo control arm matched to fenebrutinib, a Bruton's tyrosine kinase (BTK) inhibitor that blocks B-cell and myeloid cell activation.","indications":["Control arm in phase 3 trials for fenebrutinib-targeted indications (likely autoimmune/inflammatory conditions)"],"catalyst":""},{"name":"Placebo matched to ocrelizumab","genericName":"Placebo matched to ocrelizumab","slug":"placebo-matched-to-ocrelizumab","phase":"phase_3","mechanism":"This is a placebo control arm matched to ocrelizumab, the active comparator, and contains no pharmacologically active ingredient.","indications":[],"catalyst":""},{"name":"Placebo matched to prednisone","genericName":"Placebo matched to prednisone","slug":"placebo-matched-to-prednisone","phase":"marketed","mechanism":"A placebo formulation designed to match the appearance and administration route of prednisone for use as a control in clinical trials.","indications":["Clinical trial control comparator (not a therapeutic indication)"],"catalyst":""},{"name":"Placebo to Mycophenolate mofetil","genericName":"Placebo to Mycophenolate mofetil","slug":"placebo-to-mycophenolate-mofetil","phase":"marketed","mechanism":"Mycophenolate mofetil is an immunosuppressant that selectively inhibits inosine monophosphate dehydrogenase (IMPDH), reducing proliferation of T and B lymphocytes.","indications":["Prevention of organ rejection in renal, cardiac, and hepatic transplant recipients","Active lupus nephritis","Autoimmune conditions (off-label use in various settings)"],"catalyst":""},{"name":"Placebo to adalimumab","genericName":"Placebo to adalimumab","slug":"placebo-to-adalimumab","phase":"marketed","mechanism":"Placebo is an inert substance with no active pharmacological mechanism.","indications":["Clinical trial control arm (comparator to adalimumab in various inflammatory and autoimmune conditions)"],"catalyst":""},{"name":"Placebo to bevacizumab","genericName":"Placebo to bevacizumab","slug":"placebo-to-bevacizumab","phase":"phase_3","mechanism":"Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), preventing its interaction with its receptor and thereby inhibiting angiogenesis.","indications":["Metastatic colorectal cancer","Non-small cell lung cancer","Breast cancer","Glioblastoma","Renal cell carcinoma"],"catalyst":""},{"name":"Placebo to tocilizumab","genericName":"Placebo to tocilizumab","slug":"placebo-to-tocilizumab","phase":"marketed","mechanism":"Tocilizumab is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor, inhibiting the pro-inflammatory IL-6 signaling pathway.","indications":["Rheumatoid arthritis (moderate to severe)","Giant cell arteritis","Polyarticular juvenile idiopathic arthritis","Systemic sclerosis-associated interstitial lung disease","Cytokine release syndrome (CAR-T cell induced)"],"catalyst":""},{"name":"Prednisone/Prednisolone/Methylprednisolone","genericName":"Prednisone/Prednisolone/Methylprednisolone","slug":"prednisone-prednisolone-methylprednisolone","phase":"marketed","mechanism":"Prednisone, prednisolone, and methylprednisolone are corticosteroids that bind to glucocorticoid receptors in the cytoplasm, translocate to the nucleus, and suppress inflammatory gene expression and immune cell activation.","indications":["Rheumatoid arthritis and other autoimmune inflammatory conditions","Adrenocortical insufficiency (Addison's disease)","Allergic reactions and angioedema","Asthma and chronic obstructive pulmonary disease exacerbations","Cerebral edema"],"catalyst":""},{"name":"RO0503821 (1x/2 Weeks)","genericName":"RO0503821 (1x/2 Weeks)","slug":"ro0503821-1x-2-weeks","phase":"phase_3","mechanism":"RO0503821 is a bispecific antibody that simultaneously engages two distinct molecular targets to enhance immune activation and tumor cell killing.","indications":["Solid tumors or hematologic malignancies (specific indication not publicly disclosed)"],"catalyst":""},{"name":"RO0503821 (1x/4 Weeks)","genericName":"RO0503821 (1x/4 Weeks)","slug":"ro0503821-1x-4-weeks","phase":"phase_3","mechanism":"RO0503821 is a small molecule that targets the S1P1 receptor.","indications":["Relapsing forms of multiple sclerosis"],"catalyst":""},{"name":"RO4917838","genericName":"RO4917838","slug":"ro4917838","phase":"phase_3","mechanism":"RO4917838 is a small molecule that targets the CDK9 protein.","indications":["Metastatic non-small cell lung cancer","Metastatic breast cancer"],"catalyst":""},{"name":"RO5027838","genericName":"RO5027838","slug":"ro5027838","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RO7121932 SC","genericName":"RO7121932 SC","slug":"ro7121932-sc","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RO7234292","genericName":"RO7234292","slug":"ro7234292","phase":"phase_3","mechanism":"RO7234292 is a monoclonal antibody that targets and inhibits Claudin 18.2 (CLDN18.2), a tumor-associated antigen expressed on gastric and other cancer cells.","indications":["Gastric cancer (gastric adenocarcinoma)","Gastroesophageal junction cancer"],"catalyst":""},{"name":"RO7234292 (RG6042)","genericName":"RO7234292 (RG6042)","slug":"ro7234292-rg6042","phase":"phase_3","mechanism":"RO7234292 is a small molecule antisense oligonucleotide that targets the SMN2 gene to increase production of the survival motor neuron protein.","indications":["Spinal muscular atrophy"],"catalyst":""},{"name":"RO7623066","genericName":"RO7623066","slug":"ro7623066","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ranibizumab refill exchange","genericName":"Ranibizumab refill exchange","slug":"ranibizumab-refill-exchange","phase":"phase_3","mechanism":"Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and vascular permeability in the eye.","indications":["Neovascular (wet) age-related macular degeneration","Diabetic macular edema","Retinal vein occlusion","Diabetic retinopathy","Myopic choroidal neovascularization"],"catalyst":""},{"name":"Recombinant Activated Factor VII","genericName":"Recombinant Activated Factor VII","slug":"recombinant-activated-factor-vii","phase":"phase_3","mechanism":"Recombinant Activated Factor VII (rFVIIa) directly activates the extrinsic coagulation pathway to promote thrombin generation and hemostasis.","indications":["Hemophilia A or B with inhibitors","Factor VII deficiency","Bleeding episodes in patients with coagulation disorders"],"catalyst":""},{"name":"Renodapt","genericName":"Renodapt","slug":"renodapt","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Rituximab IV","genericName":"Rituximab IV","slug":"rituximab-iv","phase":"phase_3","mechanism":"Rituximab IV works by targeting and depleting CD20-positive B cells.","indications":["Non-Hodgkin's lymphoma","Chronic lymphocytic leukemia"],"catalyst":""},{"name":"Rituxumab","genericName":"Rituxumab","slug":"rituxumab","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ro 205-2349","genericName":"Ro 205-2349","slug":"ro-205-2349","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Satralizumab 120 mg","genericName":"Satralizumab 120 mg","slug":"satralizumab-120-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Second-Line Chemotherapy","genericName":"Second-Line Chemotherapy","slug":"second-line-chemotherapy","phase":"phase_3","mechanism":"Second-line chemotherapy refers to cytotoxic drug regimens administered after first-line treatment failure or progression in cancer patients.","indications":["Advanced or metastatic cancers after first-line chemotherapy failure or progression"],"catalyst":""},{"name":"Sefaxersen (RO7434656)","genericName":"Sefaxersen (RO7434656)","slug":"sefaxersen-ro7434656","phase":"phase_3","mechanism":"Sefaxersen is a direct Factor Xa inhibitor.","indications":["Treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE)"],"catalyst":""},{"name":"Sham Procedure","genericName":"Sham Procedure","slug":"sham-procedure","phase":"phase_3","mechanism":"The Sham Procedure is a placebo treatment with no active pharmaceutical ingredient.","indications":["Various conditions"],"catalyst":""},{"name":"Silrolimus","genericName":"Silrolimus","slug":"silrolimus","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Streptozotocin","genericName":"Streptozotocin","slug":"streptozotocin","phase":"phase_3","mechanism":"Small molecule","indications":["Pancreatic Neuroendocrine Tumor"],"catalyst":""},{"name":"Supportive treatment","genericName":"Supportive treatment","slug":"supportive-treatment","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Syfovre™","genericName":"Syfovre™","slug":"syfovre","phase":"marketed","mechanism":"Syfovre is an anti-VEGF aptamer that binds and inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth and leakage in the retina.","indications":["Geographic atrophy secondary to age-related macular degeneration (AMD)"],"catalyst":""},{"name":"TT Vaccine","genericName":"TT Vaccine","slug":"tt-vaccine","phase":"phase_3","mechanism":"The TT vaccine works by stimulating the body to produce antibodies against diphtheria and tetanus toxins.","indications":["Prevention of diphtheria and tetanus"],"catalyst":""},{"name":"Tociliuzumab","genericName":"Tociliuzumab","slug":"tociliuzumab","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Topotecan (Chemotherapy)","genericName":"Topotecan (Chemotherapy)","slug":"topotecan-chemotherapy","phase":"phase_3","mechanism":"Topotecan is a topoisomerase I inhibitor that works by interfering with the enzyme topoisomerase I, which is involved in DNA replication and repair.","indications":["Metastatic ovarian cancer","Small cell lung cancer"],"catalyst":""},{"name":"Trastuzumab IV","genericName":"Trastuzumab IV","slug":"trastuzumab-iv","phase":"phase_3","mechanism":"Trastuzumab IV works by targeting and binding to the HER2/neu receptor on cancer cells, triggering an immune response and inhibiting cell growth.","indications":["Adjuvant treatment of HER2-positive breast cancer","Treatment of HER2-positive metastatic breast cancer"],"catalyst":""},{"name":"Vitamin D and calcium supplementation","genericName":"Vitamin D and calcium supplementation","slug":"vitamin-d-and-calcium-supplementation","phase":"marketed","mechanism":"Vitamin D and calcium supplementation work together to promote bone mineralization and maintain serum calcium levels by enhancing intestinal calcium absorption and regulating calcium-phosphate homeostasis.","indications":["Osteoporosis prevention and treatment","Vitamin D deficiency","Hypocalcemia","Bone health maintenance in aging populations"],"catalyst":""},{"name":"XELODA [capecitabine]","genericName":"XELODA [capecitabine]","slug":"xeloda-capecitabine","phase":"marketed","mechanism":"Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth.","indications":["Metastatic colorectal cancer","Metastatic breast cancer","Gastric cancer","Pancreatic cancer"],"catalyst":""},{"name":"Zelboraf","genericName":"Zelboraf","slug":"zelboraf","phase":"marketed","mechanism":"Aspartyl/asparaginyl beta-hydroxylase, Ferrochelatase, mitochondrial, Dual specificity mitogen-activated protein kinase kinase 5","indications":["Erdheim-Chester Disease","Malignant Melanoma with BRAF V600E Mutation"],"catalyst":""},{"name":"[ 14C]-labeled RO7269162","genericName":"[ 14C]-labeled RO7269162","slug":"14c-labeled-ro7269162","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[12C] RO7049389","genericName":"[12C] RO7049389","slug":"12c-ro7049389","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"aPCC","genericName":"aPCC","slug":"apcc","phase":"phase_3","mechanism":"aPCC is an anticoagulant that works by replacing and controlling the activity of natural anticoagulant proteins in the blood.","indications":["Reversal of anticoagulation due to warfarin or other vitamin K antagonists in patients with acute major bleeding or at high risk of bleeding","Prophylaxis of bleeding in patients with hemophilia A or B undergoing surgery"],"catalyst":""},{"name":"aleglitazar+metformin","genericName":"aleglitazar+metformin","slug":"aleglitazar-metformin","phase":"phase_3","mechanism":"Aleglitazar, a PPARα/γ agonist, and metformin, a biguanide, work together to improve insulin sensitivity and glucose uptake in the body.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"anti-IL-2R","genericName":"anti-IL-2R","slug":"anti-il-2r","phase":"phase_3","mechanism":"anti-IL-2R drugs target the interleukin-2 receptor to prevent T-cell activation.","indications":["Prevention of organ rejection in kidney transplant recipients"],"catalyst":""},{"name":"antihistamine","genericName":"antihistamine","slug":"antihistamine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"bitopertin [RO4917838]","genericName":"bitopertin [RO4917838]","slug":"bitopertin-ro4917838","phase":"phase_3","mechanism":"Bitopertin is a glycine receptor antagonist.","indications":["Schizophrenia"],"catalyst":""},{"name":"bitopertin [RO4917838] level 1","genericName":"bitopertin [RO4917838] level 1","slug":"bitopertin-ro4917838-level-1","phase":"phase_3","mechanism":"Bitopertin is a glycine transporter 1 (GlyT1) inhibitor that increases synaptic glycine levels to enhance NMDA receptor function in the brain.","indications":["Schizophrenia (negative and cognitive symptoms, as adjunctive therapy)","Autism spectrum disorder (investigational)"],"catalyst":""},{"name":"bitopertin [RO4917838] level 2","genericName":"bitopertin [RO4917838] level 2","slug":"bitopertin-ro4917838-level-2","phase":"phase_3","mechanism":"Bitopertin is a glycine receptor antagonist.","indications":["Schizophrenia"],"catalyst":""},{"name":"calcipotriol hydrate [Daivonex]","genericName":"calcipotriol hydrate [Daivonex]","slug":"calcipotriol-hydrate-daivonex","phase":"marketed","mechanism":"Calcipotriol is a vitamin D3 analog that binds to the vitamin D receptor to regulate skin cell differentiation and proliferation, reducing excessive keratinocyte growth.","indications":["Plaque psoriasis","Psoriatic dermatitis"],"catalyst":""},{"name":"dexpantenol [Bepantol]","genericName":"dexpantenol [Bepantol]","slug":"dexpantenol-bepantol","phase":"phase_3","mechanism":"Dexpantenol is a topical antiviral agent that works by inhibiting the replication of certain viruses.","indications":["Treatment of herpes simplex virus infections"],"catalyst":""},{"name":"eloxatin","genericName":"eloxatin","slug":"eloxatin","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"enfuvirtide [Fuzeon]","genericName":"enfuvirtide [Fuzeon]","slug":"enfuvirtide-fuzeon","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"epoetin alfa or beta","genericName":"epoetin alfa or beta","slug":"epoetin-alfa-or-beta","phase":"phase_3","mechanism":"Epoetin alfa and beta stimulate erythropoiesis by binding to the erythropoietin receptor.","indications":["Anemia associated with chronic kidney disease","Anemia associated with chemotherapy"],"catalyst":""},{"name":"epoetin beta [NeoRecormon]","genericName":"epoetin beta [NeoRecormon]","slug":"epoetin-beta-neorecormon","phase":"marketed","mechanism":"Epoetin beta is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.","indications":["Anemia associated with chronic kidney disease","Anemia in patients with cancer receiving chemotherapy","Anemia in patients with HIV infection receiving antiretroviral therapy","Perioperative anemia in patients undergoing elective surgery"],"catalyst":""},{"name":"erythromycin [Eritex]","genericName":"erythromycin [Eritex]","slug":"erythromycin-eritex","phase":"phase_3","mechanism":"Erythromycin inhibits protein synthesis by binding to the 50S subunit of the bacterial ribosome.","indications":["Acute bacterial exacerbation of chronic bronchitis","Acute bacterial sinusitis","Community-acquired pneumonia","Pharyngitis and tonsillitis caused by Streptococcus pyogenes","Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes"],"catalyst":""},{"name":"fusidic acid [Verutex]","genericName":"fusidic acid [Verutex]","slug":"fusidic-acid-verutex","phase":"phase_3","mechanism":"Fusidic acid inhibits bacterial protein synthesis by binding to the elongation factor G.","indications":["Bacterial infections, including osteomyelitis and septic arthritis"],"catalyst":""},{"name":"ibandronate [Bonviva/Boniva]","genericName":"ibandronate [Bonviva/Boniva]","slug":"ibandronate-bonviva-boniva","phase":"marketed","mechanism":"Ibandronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking the mevalonate pathway in osteoclasts.","indications":["Osteoporosis in postmenopausal women","Bone metastases in breast cancer","Hypercalcemia of malignancy"],"catalyst":""},{"name":"interferon-a-2a","genericName":"interferon-a-2a","slug":"interferon-a-2a","phase":"phase_3","mechanism":"Interferon-alpha-2a works by stimulating the body's immune system to fight viral infections and cancer.","indications":["Multiple myeloma","Hairy cell leukemia"],"catalyst":""},{"name":"non-biological DMARDs","genericName":"non-biological DMARDs","slug":"non-biological-dmards","phase":"marketed","mechanism":"Non-biological DMARDs are small-molecule drugs that suppress the immune system by inhibiting intracellular signaling pathways to reduce inflammation and joint damage in autoimmune diseases.","indications":["Rheumatoid arthritis","Systemic lupus erythematosus","Psoriatic arthritis","Ankylosing spondylitis"],"catalyst":""},{"name":"pemetrexel","genericName":"pemetrexel","slug":"pemetrexel","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"placebo to tocilizumab IV","genericName":"placebo to tocilizumab IV","slug":"placebo-to-tocilizumab-iv","phase":"phase_3","mechanism":"Tocilizumab is an interleukin-6 receptor antagonist that inhibits the inflammatory response by blocking the action of interleukin-6.","indications":["Rheumatoid arthritis","Juvenile idiopathic arthritis","Giant cell arteritis","Carvastatin-induced giant cell arteritis","Polyarticular juvenile idiopathic arthritis"],"catalyst":""},{"name":"placebo to tocilizumab SC","genericName":"placebo to tocilizumab SC","slug":"placebo-to-tocilizumab-sc","phase":"phase_3","mechanism":"Tocilizumab is an interleukin-6 receptor antagonist that inhibits the inflammatory response by blocking the action of interleukin-6.","indications":["Rheumatoid arthritis","Juvenile idiopathic arthritis","Cytokine release syndrome"],"catalyst":""},{"name":"rituximab [MabThera/Rituxan]","genericName":"rituximab [MabThera/Rituxan]","slug":"rituximab-mabthera-rituxan","phase":"marketed","mechanism":"Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system.","indications":["Non-Hodgkin's lymphoma (B-cell)","Chronic lymphocytic leukemia (CLL)","Rheumatoid arthritis","Granulomatosis with polyangiitis (GPA)","Microscopic polyangiitis (MPA)"],"catalyst":""},{"name":"tacrolimus, low dose","genericName":"tacrolimus, low dose","slug":"tacrolimus-low-dose","phase":"marketed","mechanism":"Tacrolimus is a calcineurin inhibitor that suppresses T-cell activation by blocking the phosphatase calcineurin, thereby preventing the transcription of pro-inflammatory cytokines.","indications":["Organ transplant rejection prophylaxis (kidney, heart, liver)","Atopic dermatitis","Atopic keratoconjunctivitis","Vernal keratoconjunctivitis"],"catalyst":""},{"name":"tacrolimus, standard dose","genericName":"tacrolimus, standard dose","slug":"tacrolimus-standard-dose","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"tocilizumab SC","genericName":"tocilizumab SC","slug":"tocilizumab-sc","phase":"phase_3","mechanism":"Tocilizumab SC is an interleukin-6 receptor antagonist that blocks the action of interleukin-6, a cytokine involved in inflammation.","indications":["Rheumatoid arthritis","Juvenile idiopathic arthritis"],"catalyst":""},{"name":"tocilizumab [RoActemra/Actemra]","genericName":"tocilizumab [RoActemra/Actemra]","slug":"tocilizumab-roactemra-actemra","phase":"marketed","mechanism":"Tocilizumab is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor, inhibiting the pro-inflammatory signaling pathway driven by IL-6.","indications":["Rheumatoid arthritis (moderate to severe)","Polyarticular juvenile idiopathic arthritis","Systemic sclerosis-associated interstitial lung disease","Giant cell arteritis","Takayasu arteritis"],"catalyst":""},{"name":"valganciclovir [Valcyte]","genericName":"valganciclovir [Valcyte]","slug":"valganciclovir-valcyte","phase":"marketed","mechanism":"Valganciclovir is a prodrug that is converted to ganciclovir, which inhibits viral DNA polymerase and prevents replication of cytomegalovirus (CMV).","indications":["Cytomegalovirus (CMV) retinitis in immunocompromised patients (including HIV/AIDS)","CMV disease prevention in high-risk transplant recipients"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE5fUEtWVVZhQmQ4REFhVzkxUnlYRW9abWZ3OEFqTk9TQjAwMW5mTzFzcjR1cUtmNHZDSmlMb0lsRjdVM3huV2FjVE9Wdld5ZkxySnMxMlBXY0UydXNYbUhhYzVTQmJzcFFHOVRzX2k3RHk0ZllEcEtUZGI5NFo4QQ?oc=5","date":"2026-02-19","type":"pipeline","source":"Statista","summary":"Total sales of the Roche Group from 2013 to 2025, by division - Statista","headline":"Total sales of the Roche Group from 2013 to 2025, by division","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOS2piZ3Nua2VCYzJqS2VMcUQ1R081NWtnUXhxVGFad0RaSVJKVDZOTGd5N25iVXl3OEpWME5NMThYWkdwT3V4WUEwVkN2c3Y1cFdHcGRvXzFzU2VTM0lMSFU3RnotX2pIVnFYbTlRWTNiVGwyekJIN2hVSXdtamVvUEctOUF3WUcwV3BXd3hXczhJQ29vcFRkb1YtZnRwQnQtTnRtOExQNzVsMVhIVDB5QU45NWVhTmZ5dkFVQ0tvT1liVzItcWVhTFZR?oc=5","date":"2026-02-17","type":"pipeline","source":"GlobeNewswire","summary":"Change to the Roche Enlarged Corporate Executive Committee - GlobeNewswire","headline":"Change to the Roche Enlarged Corporate Executive Committee","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxPcTJHbS1jVDA0MHFnWDQweFFYN0RTQThtMFlmVUtweVFqdlpYbUdZYTRIWFd6dFVVS04tNjV0M0xteXhjSHpFd05DVXE2dDhQMDhOY3VJLXVEM3pKQVhReTV5NC1HR1dEQUYxWDhFRnBlaE5kTGE1eGJrMWthcHRUOHM1SmtSSEw2eGFiZks1ZEllMjFtSncyZkVRY1BSQTNCeGlaaWRRTWJsS2ZQcGJTOG9XWUdmVjlYekVOZm5DYk9nU05CRTBuaWZHV2E2WFhFTGYtRUY1dW92bEJ5cVRBN3AwNFVQZDMxcXpsVjFHaE96XzA2OWc?oc=5","date":"2026-01-30","type":"trial","source":"Citeline News & Insights","summary":"Roche Awaits Key Readouts In 2026 – Including Its Potential Biggest Ever Drug - Citeline News & Insights","headline":"Roche Awaits Key Readouts In 2026 – Including Its Potential Biggest Ever Drug - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOQ1JrYnhoLWxyQk9lV0lvZ2wtamFzZzdpOTVTNkpVNmFWclhyeGRzLVRHYV9qbGh6aFRBWUJobHhwb18tdVIzSC1PWGJtQU92UlE1WlE3YW1nRTNYSUdtSkhfQ2FvaFJrRUlPbnA4OEp2SHpFTnQ3WEhHa2ZtR25zc1dXWjF5QTRLbnc2ZUlOempmNVZTcnZQdjBtNWlrU3FLTkZnT0ZjRUZKT3JIaVVmSGdXWFZ4ZWw2MXoyQw?oc=5","date":"2025-11-03","type":"pipeline","source":"Cyril Amarchand Mangaldas","summary":"Delhi High Court’s Ruling in F. Hoffmann-La Roche Ag & Anr. V. Natco Pharma - Cyril Amarchand Mangaldas","headline":"Delhi High Court’s Ruling in F. Hoffmann-La Roche Ag & Anr. V. Natco Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxNWDRIZTI1UDZYNGkyTUhSallnQ1ppeTZVSHIwaEdiRVVRdmRQbk96elF5LWhXdUlSR2hMUTU4aGpOdERpaTBMQ0E5UDk4Tm9MSEpCdDNud3o1SnpBWjFOek44TFV6TjRhRkRCSmptY3F2eGV3QTJyZ01OR0h5bGZnb0pwVFd3c29sdTNnSlVHRTJvdnRndEoxUzI3MTczNzUxQTA5WWtSMFNGZHNweHltQU8xdmdhSGhsTDFKZEJ0ei03dG16OGdrTElLZw?oc=5","date":"2025-10-23","type":"pipeline","source":"GlobeNewswire","summary":"Changes to the Roche Enlarged Corporate Executive Committee - GlobeNewswire","headline":"Changes to the Roche Enlarged Corporate Executive Committee","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxOVXJkX1pQaFpRdjdCR29vdS0wb3ZERDczVXo4Z0JFaDBrU3FET0NMUzlTQ08tVURIRk54Uk9KLUxwcnZiMVlSRmZsR1dYTi01V2IxUzJUcHo5WWdwOXZUMW1zTmZ1SW9SeXU2MlotRTRHcXViVlpoR0M5dExNeloxWlh5MmxGMnNQSlUzeXRPWmZBZVgxdjdVR3dmWEE5QnEwWXZSOVpUNnB2SmNzZkhNODk5RG9WZFRXWE5fbTNZQm5BV25DZk95WDBlUm9Ea1FhemVoRHRfNW1vbElZcEE?oc=5","date":"2025-10-17","type":"deal","source":"Reuters","summary":"China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche - Reuters","headline":"China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-17","type":"deal","source":"South China Morning Post","summary":"Hansoh and Leads Biolabs clinch US$2.5 billion in global drug licensing deals - South China Morning Post","headline":"Hansoh and Leads Biolabs clinch US$2.5 billion in global drug licensing deals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_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?oc=5","date":"2025-10-17","type":"patent","source":"Mint","summary":"SC refuses to restrain Natco from selling generic version of Roche's Risdiplam - Mint","headline":"SC refuses to restrain Natco from selling generic version of Roche's Risdiplam","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-14","type":"patent","source":"The Economic Times","summary":"Roche moves SC against Natco’s launch of generic Risdiplam in India - The Economic Times","headline":"Roche moves SC against Natco’s launch of generic Risdiplam in India","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-10","type":"pipeline","source":"Business Standard","summary":"Natco Pharma up 6% as Delhi HC clears SMA drug, rejects Roche appeal - Business Standard","headline":"Natco Pharma up 6% as Delhi HC clears SMA drug, rejects Roche appeal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQY25LVTlnbjZmaHRJME9NX043c3JHc1BGa1FvU0Q5SHNIT21LUjZhRzFqWXM2bHBUeW1YbUxZQUFYaFdLNVI1dFFhUEtqU200T0lndkg2ZWo4SHhhUWhVX2FpZkxYdU5wNHRES3YySGIzQXlDeFQ1RmlFVXl2dTRHbF8zSUlxeWZDdzdwamh5U285ZkxX?oc=5","date":"2025-08-07","type":"pipeline","source":"Yahoo Finance","summary":"United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda - Yahoo ","headline":"United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE1STGZhVEIxQldNTUh3Vi1tVl9jU0ZTa3dYdHh0b0dxMFhQcW5abkQxRFl5TkVVYXlJbnFjaVhueTIxQ3J6Q2NHYW82R2pYVXh1eEtEdnl2dXpHdzlVZVNXQV8xY3FXVlFOeC1TeXBjTFZ1UjdlZkE?oc=5","date":"2025-04-22","type":"pipeline","source":"Pharmaceutical Technology","summary":"Roche announces $50bn US investment in pharma and diagnostics - Pharmaceutical Technology","headline":"Roche announces $50bn US investment in pharma and diagnostics","sentiment":"neutral"}],"patents":[],"drugCount":168,"phaseCounts":{"marketed":53,"phase_3":77,"phase_2":20,"phase_1":17,"discontinued":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}